Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
- Associated Therapies
- -
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Olema Pharmaceuticals, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT06016738
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
🇲🇾Clinical Trials Site, Sungai Petani, Kedah, Malaysia
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 90
- Registration Number
- NCT06001762
- Locations
- 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸Eastern Maine Medical Center (Northern Light), Brewer, Maine, United States
🇺🇸New England Cancer Specialists, Scarborough, Maine, United States
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5500
- Registration Number
- NCT05952557
- Locations
- 🇬🇧
Research Site, Whitchurch, United Kingdom
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 766
- Registration Number
- NCT05891093
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangdong, Guangzhou, China
🇨🇳Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3100
- Registration Number
- NCT05827081
- Locations
- 🇦🇺
Novartis Investigative Site, Gateshead, New South Wales, Australia
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4300
- Registration Number
- NCT05774951
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT05607004
- Locations
- 🇺🇸
Henry Ford Cancer Institute, Detroit, Michigan, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6000
- Registration Number
- NCT05514054
- Locations
- 🇺🇸
Summit Cancer Care, PC, Savannah, Georgia, United States
🇺🇸Saint Alphonsus Regional Medical Center, Boise, Idaho, United States
🇺🇸Staten Island University Hospital, Staten Island, New York, United States
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Oana Danciu
- Target Recruit Count
- 200
- Registration Number
- NCT05467891
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Arizona, Phoenix, Arizona, United States
🇺🇸Orlando Health Cancer Institute, Orlando, Florida, United States
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05306340
- Locations
- 🇺🇸
Alabama Oncology - Bruno Cancer Center, Birmingham, Alabama, United States
🇺🇸Alaska Oncology and Hematology, Anchorage, Alaska, United States
🇺🇸The Dignity Health Cancer Institute, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.